Pfizer (PFE) Net Income towards Common Stockholders Growth (1y) (2010 - 2026)
Pfizer (PFE) Net Income towards Common Stockholders Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -0.05% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 284.27% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -130.19% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -92.23% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.33% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 65.85% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -635.24% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -108.13% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -69.68% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -91.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | -68.00% |
| Jun 29, 2025 | 47.06% |
| Jun 30, 2024 | 950.00% |
| Mar 31, 2024 | -600.00% |
| Jul 2, 2023 | -105.88% |
| Apr 2, 2023 | 111.11% |
| Jul 3, 2022 | 114.41% |
| Apr 3, 2022 | -1,000.00% |
| Oct 3, 2021 | -110.63% |
| Jul 4, 2021 | -126.43% |
| Apr 4, 2021 | -99.89% |
| Sep 27, 2020 | 58,250.00% |
| Dec 31, 2019 | -27.38% |
| Sep 29, 2019 | -63.64% |
| Dec 31, 2018 | 365,800.00% |
| Jul 2, 2017 | 100.00% |
| Jul 3, 2016 | 0.00% |
| Dec 31, 2015 | -33.33% |
| Mar 29, 2015 | -93.15% |
| Dec 31, 2014 | 61.54% |